

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/559,887	Confirmation No.: Unknown
Applicant: Pagé <i>et al.</i>	PCT Appl. No.: PCT/GB2004/002429
National Phase Fld (371): December 7, 2005	PCT Filed: June 9, 2004
Docket No.: 101102-1P US	TC/A.U.: Unknown
Customer No.: 22466	Examiner: Unknown
Title: Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof	

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

All of the cited references were listed on the International Search Report and International-Type Search Report, copies of which are enclosed herewith for the convenience of the Examiner.

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Applicants also wish to make the Examiner aware of co-pending applications:

10/557,813, a PCT national phase filed on June 9, 2004.

In addition, Applicants want to make the Examiner aware that Applicants could not retrieve the reference cited as "STN International, File CHEMCATS, Accession no. 2003:2601935, "1H-Benzimidazole-5-carboxamide, 1-ethyl-N,N,2-trimethyl-", CAS Registry No. 313277-30-4," in the International Type Search Report for the priority application of the

copending application No. 10/557,813 in spite of Applicants' diligent efforts. Applicants suspect that the citation in the Search Report contains an error, which prevents Applicants from locating or retrieving the reference. However, Applicants conducted a search in the CHEMCATS database based on the mentioned CAS Registry No. 313277-30-4 and retrieved a few references which are cited in the attached SB08B forms.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101102-1P US.

Respectfully submitted,

/Jianzhong Shen/
Name: Jianzhong Shen
Reg. No.: 48,076
Date: April 4, 2006
Phone No.: 302-886-8854